Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06645886 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
A Phase 1 study of Hematologic Malignancies and Adult, sponsored by Kumquat Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 20
- Study locations
NCT06645886 is a Phase 1 study of Hematologic Malignancies and Adult that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 122 participants, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 19 states.
The verdict
NCT06645886, a Phase 1 study of Hematologic Malignancies and Adult, is actively recruiting participants, sponsored by Kumquat Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG KQB198
Study Locations (20)
Texas
- Texas Oncology Austin Central - Austin
- MD Anderson Cancer Center - Houston
California
- University of California, San Francisco (UCSF) - San Francisco
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Moffitt Cancer Center - Tampa
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
North Carolina
- Duke University Medical Center - Durham
Ohio
- Oncology Hematology Cincinnati - Cincinnati
Tennessee
- Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06645886
The ClinicalTrials.gov registry entry for NCT06645886 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (95% lower). The listed sponsor is Kumquat Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Dasatinib is the first listed.
NCT06645886 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06645886 about?
NCT06645886 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies". The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Do...
What is the current status of trial NCT06645886?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2024-12-09. Estimated completion is 2028-02.
What conditions does trial NCT06645886 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Adult.
What interventions are being tested in trial NCT06645886?
The interventions under investigation include: Dasatinib (DRUG), KQB198 (DRUG).
Who is sponsoring clinical trial NCT06645886?
This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06645886 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.